THE CHANGING LANDSCAPE OF BOTULINUM TOXIN DELIVERY

Revance's RT002 beats BOTOX in mid-stage study; shares up 58% premarket--

Oct 29 2015, 08:44 ET | About: Revance Therapeutics, ... (RVNC) | By: Douglas W. House, SA News Editor